Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Long-Term Deferred Tax (2018 - 2019)

Historic Long-Term Deferred Tax for Zevra Therapeutics (ZVRA) over the last 4 years, with Q4 2019 value amounting to $67.7 million.

  • Zevra Therapeutics' Long-Term Deferred Tax rose 1219.79% to $67.7 million in Q4 2019 from the same period last year, while for Dec 2019 it was $67.7 million, marking a year-over-year increase of 1219.79%. This contributed to the annual value of $67.7 million for FY2019, which is 1219.79% up from last year.
  • As of Q4 2019, Zevra Therapeutics' Long-Term Deferred Tax stood at $67.7 million, which was up 1219.79% from $60.4 million recorded in Q4 2018.
  • Zevra Therapeutics' Long-Term Deferred Tax's 5-year high stood at $67.7 million during Q4 2019, with a 5-year trough of $29.1 million in Q4 2015.
  • Moreover, its 3-year median value for Long-Term Deferred Tax was $60.4 million (2018), whereas its average is $52.4 million.
  • Per our database at Business Quant, Zevra Therapeutics' Long-Term Deferred Tax surged by 5932.88% in 2015 and then skyrocketed by 1219.79% in 2019.
  • Quarter analysis of 3 years shows Zevra Therapeutics' Long-Term Deferred Tax stood at $29.1 million in 2015, then skyrocketed by 107.41% to $60.4 million in 2018, then grew by 12.2% to $67.7 million in 2019.
  • Its Long-Term Deferred Tax was $67.7 million in Q4 2019, compared to $60.4 million in Q4 2018 and $29.1 million in Q4 2015.